Cargando…
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data
BACKGROUND: After progression to a standard first-line platinum and gemcitabine combination (GP), there is no established second-line therapy for patients with advanced biliary tract cancers (aBTC). Indeed, literature data suggest limited activity of most second-line agents evaluated so far. METHODS...
Autores principales: | Fornaro, Lorenzo, Vivaldi, Caterina, Cereda, Stefano, Leone, Francesco, Aprile, Giuseppe, Lonardi, Sara, Silvestris, Nicola, Santini, Daniele, Milella, Michele, Caparello, Chiara, Musettini, Gianna, Pasquini, Giulia, Falcone, Alfredo, Brandi, Giovanni, Sperduti, Isabella, Vasile, Enrico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689003/ https://www.ncbi.nlm.nih.gov/pubmed/26693938 http://dx.doi.org/10.1186/s13046-015-0267-x |
Ejemplares similares
-
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
por: Fornaro, L, et al.
Publicado: (2014) -
Comment on: ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
por: Vivaldi, Caterina, et al.
Publicado: (2016) -
Bone metastases in biliary cancers: A multicenter retrospective survey
por: Santini, D, et al.
Publicado: (2018) -
Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy
por: Casadei-Gardini, Andrea, et al.
Publicado: (2023) -
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
por: Del Re, Marzia, et al.
Publicado: (2017)